Outlook Therapeutics (OTLK) Receives a Buy from Oppenheimer

In a report released yesterday, Leland Gershell from Oppenheimer assigned a Buy rating to Outlook Therapeutics (OTLKResearch Report), with a price target of $8.00. The company’s shares closed last Monday at $0.71.

According to TipRanks.com, Gershell is a 3-star analyst with an average return of 2.7% and a 42.4% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.

Currently, the analyst consensus on Outlook Therapeutics is a Moderate Buy with an average price target of $6.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.76 and a one-year low of $0.50. Currently, Outlook Therapeutics has an average volume of 3.41M.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OTLK in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.